BiotechTube

Lenvatinib + Nivolumab

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anaplastic Thyroid Cancer

Conditions

Anaplastic Thyroid Cancer

Trial Timeline

Jul 2, 2019 → Dec 1, 2026

NCT ID
NCT05696548

About Lenvatinib + Nivolumab

Lenvatinib + Nivolumab is a phase 2 stage product being developed by Ono Pharmaceutical for Anaplastic Thyroid Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05696548. Target conditions include Anaplastic Thyroid Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05696548Phase 2Active

Competing Products

20 competing products in Anaplastic Thyroid Cancer

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
41
efatutazone + paclitaxelDaiichi SankyoPhase 2
52
Lenvatinib 24 mgEisaiPhase 2
52
durvalumab + tremelimumabAstraZenecaPhase 1
33
PembrolizumabMerckPhase 2
52
LDK378 + AUY922NovartisPhase 1
33
ceritinibNovartisPre-clinical
23
LDK378NovartisPhase 1
33
CeritinibNovartisPhase 2
52
Gemcitabine + ribociclib + sonidegib + trametinib + filgrastimNovartisPhase 1
33
dabrafenib/trametinibNovartisPhase 2
52
Trametinib + PaclitaxelNovartisPhase 1
33
Alectinib + CrizotinibRochePhase 3
77
Sunitinib MalatePfizerPhase 2
51
Crizotinib (PF-02341066)PfizerPhase 2
51
LorlatinibPfizerPhase 2
51
CrizotinibPfizerPhase 1/2
40
Cemiplimab + XL092Regeneron PharmaceuticalsPhase 1
32
Etirinotecan pegolNektar TherapeuticsPhase 2
47
BevacizumabNovocurePhase 2
47

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved
85
Abatacept + Placebo matching with Abatacept + MethotrexateApproved
85
Rivastigmine transdermal patchApproved
85
Sitagliptin phosphatePhase 3
77
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3
77